CAR-T cells take on donor infusion in battle against stubborn leukemia
NCT ID NCT07441291
First seen Feb 28, 2026 · Last updated May 21, 2026 · Updated 9 times
Summary
This study tests whether a powerful immune cell therapy (CAR-T) works better than standard donor immune cells (DLI) to wipe out leftover leukemia in patients who had a stem cell transplant. About 70 people aged 3 to 80 with a certain type of leukemia and minimal residual disease will be randomly assigned to one of the two treatments. The main goal is to see which approach clears the remaining cancer cells more effectively at 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ALL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.